AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
In late 2018, AstraZeneca engaged with the STRATiGRAD programme to co-fund 12 studentships in the areas of multiomic profiling with an emphasis on oncology, respiratory and hepatology, with the aim of driving forward innovation in these fields.
Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
Bruker have engaged with the STRATiGRAD programme since its inception and have played a key role in the intervening years developing the field of Metabolomics via application of its high performance instrumentation.
partners line 2
Merck is a vibrant science and technology company. Science is at the heart of everything Merck does – driving the discoveries Merck makes and the technologies they create. From prescription medicines to treat conditions such as cancer and infertility, Merck’s goal is to make a difference to millions of lives.
Merck joined the STRATiGRAD programme in 2012 and have supported the programme over the last seven years, supporting projects in multiple therapeutic areas and engaging with students in their development both in the academic and business arena.
Medical Research Council
MRC's work ranges from laboratory research, for example on genes and molecules, right through to research with people, such as clinical trials and population studies. Their science is split into six broad areas of research: infections and immunity, molecular and cellular medicine, neurosciences and mental health, population and systems medicine, global health and translational research.
partners line 3
Nestlé is the world’s largest food and beverage company. They aim to enhance quality of life and contribute to a healthier future. Driven by that, Nestle aim to help shape a better world and inspire people to live healthier lives.
Nestlé joined the STRATiGRAD programme in 2017 and have added an additional dimension to the research the Programme aims to achieve in the metabolomics and phenotyping. Nestlé have supported studentships with a microbiome, nutrition and associated health conditions.
Gynaecology – PCOS, Critical care – specifically kidney or lung injury and Oncology – specify the cancer types we have worked with.
NIHR National Institute for Health Research
The NIHR is the nation’s largest funder of health and care research. Their people, programmes, centres of excellence and systems together represent the most integrated health research system in the world. They have transformed research in and for the NHS and helped to shape the health research landscape more broadly.
Partners line 4
The Servier group is a French Pharmaceutical company dedicated to therapeutic progress to serve patient needs. Servier continuous pursue innovation in five areas of excellence – cardiovascular, immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes.
Servier have engaged with the STRATiGRAD programme since early 2014 and have continued to be a committed and enthusiastic partner of the programme over the last 5 years. Work with Servier has led to expansion in knowledge in the areas of gut health, the microbiome, inflammatory diseases and drug metabolism.